Roche launches Global Access Program for HIV viral load testing
26 September 2014 | By Roche
Roche announced the launch of a new Global Access Program for HIV viral load testing...
List view / Grid view
News
Pfizer completes acquisition of InnoPharma
26 September 2014 | By Pfizer
Pfizer Inc. announced that it has completed its acquisition of the pharmaceutical development company, InnoPharma, Inc., following receipt of United States regulatory approval from all government authorities required by the agreement and other closing conditions...
Almirall’s aclidinium bromide/formoterol fumarate recommended for approval in Europe to treat COPD
26 September 2014 | By Almirall S.A
Almirall S.A. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for the regulatory approval of Duaklir® Genuair® (aclidinium bromide/formoterol fumarate) in all EU member states...
Novo Nordisk establishes new obesity research unit in Seattle
26 September 2014 | By Novo Nordisk
Novo Nordisk announced that the company will establish a new obesity research unit in Seattle, Washington, in the US...
AbbVie’s HUMIRA® (adalimumab) receives U.S. FDA approval for the treatment of pediatric patients with moderately to severely active Crohn’s disease
26 September 2014 | By AbbVie
AbbVie announced that the U.S. Food and Drug Administration has approved HUMIRA® (adalimumab) for reducing signs and symptoms, and achieving and maintaining clinical remission, in pediatric Crohn's disease patients 6 years of age and older when certain other treatments have not worked well enough...
Dolomite and Lab on a Chip launch video competition to win $2,500 of microfluidic equipment
25 September 2014 | By kdm communications
Microfluidics specialist Dolomite has teamed up with Lab on a Chip and the Chemical and Biological Microsystems Society to create the first ever MicroTAS Video Competition...
Roche’s Avastin and Xeloda show benefit for women with HER2-negative metastatic breast cancer in two new Phase III studies
25 September 2014 | By Roche
Roche announced results from the phase III IMELDA study which showed that the combination of Avastin (bevacizumab) plus Xeloda (capecitabine) chemotherapy as a maintenance treatment following initial induction treatment with Avastin-based therapy resulted in clinically meaningful gains in overall survival...
GlaxoSmithKline plc appoints Sir Philip Hampton to the Board of Directors
25 September 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that Sir Philip Hampton will join the Board of the company as Non-Executive Director from 1 January 2015 and will become Deputy Chairman with effect from 1 April 2015...
MedImmune and Cancer Research UK establish joint CRUK-MEDI Alliance Laboratory to develop new biologic cancer medicines
25 September 2014 | By AstraZeneca
AstraZeneca announced that MedImmune, its global biologics research and development arm, and Cancer Research UK, with its commercial arm, Cancer Research Technology (CRT), have entered into an innovative collaboration to establish a joint laboratory in Cambridge, UK...
Helsinn announces that pivotal Phase III trial data for Anamorelin in ROMANA 1 and 2 studies in non-small cell lung cancer patients with anorexia-cachexia will be presented at the 38th European Society for Medical Oncology (ESMO) Congress in 2014
25 September 2014 | By Helsinn
Helsinn Group announces that Phase III data from the largest trial program of its kind to date in anamorelin, a novel, once-daily ghrelin receptor agonist in development for cancer-anorexia-cachexia (CACS) in non-small cell lung cancer will be presented at the 38th European Society for Medical Oncology Congress...
Photocure: Expert consensus on the optimal use of Cysview® BLC published in Nature Reviews Urology
25 September 2014 | By Photocure ASA
Cysview® improves detection of Non-Muscle Invasive Bladder Cancer (NMIBC) beyond that achieved with current standard of care...
SAFC and Baxter BioPharma Solutions collaborate on complete ADC offering
24 September 2014 | By Sigma-Aldrich
Sigma-Aldrich Corporation’s SAFC® Commercial custom manufacturing services business unit, and Baxter’s BioPharma Solutions business have established a collaborative manufacturing agreement...
Gilead’s investigational tenofovir alafenamide (TAF)-based single tablet HIV regimen meets 48-week primary objective in two Phase 3 studies
24 September 2014 | By Gilead
Gilead Sciences, Inc. announced that two Phase 3 clinical trials (Studies 104 and 111) evaluating an investigational once-daily single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection in treatment-naïve adults met their primary objectives...
Expiration of the U.S. Tender Offer for CFR Pharmaceuticals S.A.
24 September 2014 | By Abbott
Abbott announced the expiration of the tender offer for the purchase from U.S. holders of the ordinary shares of CFR Pharmaceuticals S.A., a Chilean corporation...
Quotient Clinical showcases ‘Gold Standard’ Human ADME studies and applications at ISSX/JSSX 2014
24 September 2014 | By kdm communications
Quotient Clinical, the Translational Pharmaceutics Company, will present a symposium and three poster publications at the forthcoming 19th North American ISSX Meeting / 29th JSSX Meeting (ISSX/JSSX 2014) from October 19th to 23rd in San Francisco, USA...
